Asia Biotech Live
LATEST UPDATES » Vol 24, No 01, January 2020 – Empowering the Patient - Personalization of Diabetes Management       » First of its kind Human Heart-in-a-Jar Model for therapeutic solutions       » China's National Vaccine Tracking System set to be completed in 2020       » China's amended drug administration law kicks in       » Human activity puts Chinese plant biodiversity at risk, study finds       » Contributory effects of each brain cell type in development of Alzheimer's Disease      
Australian medical life sciences company expands nutraceutical business to the USA
Medlab Clinical Ltd (MDC) signs a Heads of Agreement with the American Nutritional Corp Inc. (ANC), entering the US market using MDC’s existing nutraceutical products.

ANC is a US entity with audited and approved manufacturing capabilities for several extremely large institutional US brands.

The Australian based medical life science company, MDC develops therapeutic pathways for diagnosed chronic diseases as well as pain management, depression, and obesity. Several of MDC’s current, unique nutraceuticals are well positioned for ANC clients. This deal should see current MDC products enter both medical and consumer markets with larger, existing companies already strong in branding and distribution. Whilst Medlab will be featured on the label, the overall intent is to rebrand to suit the client’s general branding strategy.

Commercial terms and specific distribution partners are to be finalised through execution of a definitive commercial agreement. The first US launch of MDC products is predicted to occur within December 2019.

Medlab CEO, Dr Sean Hall said “having access to clients of this calibre and being able to tap into their supply chains is very exciting and a great opportunity to truly enter into the US nutraceutical market. It is our patents, research, and strong clinical capabilities that makes us attractive.”

In addition to the USA, MDC intends to venture into other potential international territories as a number of these institutional companies’ market internationally or are planning for expansion.

The agreement is also an opportunity to expand the relationship with ANC and capitalize on their manufacturing capabilities, providing ongoing economies of scale for the local market.


Click here for the complete issue.

news Joining Forces to Elevate Asia's Healthcare Industry
news 4th Global Feed Summit draws Feed Producers, Technology Providers, Raw Materials Suppliers to Bangkok for Key Discussions
news 2nd China Pharma Digital Innovation Summit to be held in Shanghai
news 2nd China Healthcare Digital Innovation Summit to be held in Shanghai

About Us
Available issues
Editorial Board
Letters to Editor
Contribute to APBN
Advertise with Us
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Deborah Seah
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
Copyright© 2020 World Scientific Publishing Co Pte Ltd  •  Privacy Policy